Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study

BACKGROUND: Dual blockade of immune checkpoint and angiogenesis is an effective strategy for multiple cancers. Camrelizumab is a monoclonal antibody against PD-1, and famitinib is a multitargeted receptor tyrosine kinase inhibitor with antiangiogenesis and antiproliferation activities against tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Yuan-Yuan, Sun, Zhongquan, Han, Weiqing, Zou, Qing, Xing, Nianzeng, Luo, Hong, Zhang, Xuepei, He, Chaohong, Bian, Xiao-Jie, Cai, Jinling, Chen, Chunxia, Wang, Quanren, Ye, Ding-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092172/
https://www.ncbi.nlm.nih.gov/pubmed/35537782
http://dx.doi.org/10.1136/jitc-2021-004427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092172/
https://www.ncbi.nlm.nih.gov/pubmed/35537782
http://dx.doi.org/10.1136/jitc-2021-004427

Ejemplares similares